Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4

Inclusion Criteria:

   - ANC ≥ 1.5 x 109/L without myeloid growth factor support for 7 days preceding lab
   assessment

   - Hgb ≥ 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if Hgb corrected to ≥ 9 g/dL
   (90 g/L) as by growth factor or transfusion prior to PET scan

   - Platelet count ≥ 100 x 109/L w/o blood transfusions for 7 days preceding lab
   assessment

   - Bilirubin ≤ 1.5 x upper limit of normal (ULN) except for pts with documented history
   of Gilbert's disease

   - ALT ≤ 2.5 x ULN

   - AST ≤ 2.5 x ULN

   - Alkaline phosphatase (AP) ≤ 3 x ULN

   - If a women of childbearing potential (WCBP): negative early pregnancy test (EPT)

   - Karnofsky Performance Status (KPS) ≥ 60

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Has already begun non-surgical therapy for any recurrence, prior to the first
   [18F]-C-SNAT4 PET/CT scan

   - Severe/uncontrolled inter-current illness within the previous 28 days prior to PET
   scan.

   - Any other significant co-morbid conditions that in the opinion of the Investigator
   would impair study participation or cooperation.

   - History of allergic reactions to IV contrasts or reactions attributed to compounds of
   similar chemical or biological composition to [18F]-C-SNAT4 used in study.

   - Pregnant or nursing

   - Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot
   fit through the PET/CT bore (diameter 70 cm).